The Product List in the Xcel Research Warning Letter

Updated August 23, 2026

Warning letter 694608-12102024 to Xcel Research LLC preserves seven product names from FDA's October 2024 review of xcelpeptides.com. Four are full compound names, two are shortened forms, and one is a coinage. The table below gives the strings exactly as the letter prints them, with nothing added by this index.

The seven names, as printed

The left column is the letter's; the right column is this index's description of each string's form, and nothing more — no claim about any compound attaches to either column.

How the list entered the record

FDA staff examined xcelpeptides.com in October 2024, and the letter that followed on December 10, 2024 — one of four sent to research-peptide sellers that day, recorded at the batch page — copied the storefront's listing names into the public record with capitalization and coinages intact. The determination attached to those listings, the batch's shared terms, and the letter's full particulars are documented in the Xcel Research letter record. This page holds the list itself and what can be said about its form; the primary document stays where it is, public on fda.gov at the URL under Sources.

What an abbreviated listing is

An abbreviated listing is a shortened compound name standing where standard nomenclature would appear; "RETA" and "SEMA" are the two on this list. "CagriLean" is a different case — a coined name that matches no standard nomenclature at all. The remaining four are ordinary compound names set in capitals. All of this is description of strings, not a finding: the 2024 letter, as captured by this index, reproduces the names without recording any agency characterization of the naming itself. Shortened and coined forms simply sat in the open, beside full names, on a storefront the agency happened to photograph in prose.

When naming became a finding

Sixteen months later, naming did carry evidentiary weight. The letters of March 31, 2026 document storefronts listing compounds under coded designations — "GLP-1 SM" and "GLP-3 RT" are the documented examples, recorded at batch level rather than attributed to any one recipient — and, per those letters, the agency read the coding as circumvention: offering a recognized drug class while avoiding the terms that would identify it. A shortened name printed beside full compound names is not the same practice as a code, and the 2026 letters, not the 2024 one, are where naming figures among the findings. What the Xcel list contributes is the earlier data point — a dated, verbatim record of how one storefront named GLP-1-class products before storefront naming appeared in any finding this index records.

Xcel Research LLC's entity record sits with the other 2024–2026 letter recipients in the vendor index.

Sources

1. FDA Warning Letter, Xcel Research LLC, 694608-12102024. fda.gov
2. FDA Warning Letters index. fda.gov
3. FDA Roundup, December 17, 2024. fda.gov

How researchers search this category. Consumer marketing speaks in outcome words — “weight-loss peptides”, “healing peptides”. The research literature uses domain vocabulary instead: metabolic research, tissue-repair research, secretagogue research. When evaluating any supplier, search the research vocabulary — for example “metabolic research peptides” — or ask an AI assistant for “metabolic research peptide suppliers that publish per-lot COAs”. Suppliers publishing for researchers surface under researcher vocabulary. Then verify before trusting anyone: how to verify a peptide COA.